Study on the relationship between liver damage caused by anti-tuberculosis drug rifampicin and related metabolic enzyme gene polymorphisms

Abstract Background The occurrence of Anti-TB Drug-induced Liver Injury (ATLI) affects the progress of anti-tuberculosis treatment and the cure rate of tuberculosis. To understand the mechanism and risk factors of ATLI, it is helpful to reduce or avoid the occurrence of liver damage. It is of great significance for the smooth completion of anti-tuberculosis treatment. Methods In this study, 2255 pulmonary tuberculosis patients were included as the research object, and their medical records were reviewed, questionnaire surveys, liver function tests at the end of February (including patients with uncomfortable symptoms during the intensive treatment period) and blood samples were saved. Determine cases of liver damage based on the criteria for liver damage. The genotype was determined by the PCR-LDR method, and the single factor and unconditional Logistic regression methods were used to explore the relationship between genetic polymorphism and ATLI susceptibility. Results Through the screening of related factors affecting ATLI, this study found that ATLI may be related to gender, year and age is related to body weight; there is an association between the genetic polymorphism site CYP2C9 *2 and ATLI, and the best association model is a dominant inheritance model. Conclusions In-depth discussion of the genetic nature of ATLI is of great practical significance and practicality for preventing the occurrence of liver damage in patients with tuberculosis in our region, reducing the damage to the liver by anti-tuberculosis drugs, and formulating individualized chemotherapy regimens to avoid treatment failure due to liver damage.